The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Analyst Phipps says Amgen shares are up 15% year-to-date, although it remains volatile as investors debate clinical updates with MariTide given the significant market opportunity and competitive ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses due in part to development of experimental ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US ...

THOUSAND OAKS, Calif., June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a ...

THOUSAND OAKS, Calif., June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic ...